Skip to content
NeuroTechGuide

Cognito's Spectris misses primary endpoint in pivotal Alzheimer's trial

The 673-person HOPE study of 40 Hz light and sound stimulation did not beat sham overall; Cognito points to a pre-specified mild-disease subgroup and plans to talk to the FDA.

Cognito Therapeutics’ pivotal HOPE trial of Spectris, an at-home light and sound device for Alzheimer’s disease, did not meet its primary endpoint. Results were presented on November 16 as a late-breaking talk at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Across the full study group, neither the primary measure nor the secondary measures differed significantly from a sham device.

How the trial worked

Spectris is worn over the eyes and ears for about an hour a day and delivers light and sound pulsing 40 times per second, intended to drive gamma-frequency brain waves. HOPE was a 12-month, randomized, double-blind, sham-controlled study in 673 people with biomarker-confirmed Alzheimer’s and MMSE scores of 15 to 28. The primary endpoint was a composite of a cognition test (MMSE) and a daily-function scale (ADCS-ADL).

In a pre-specified subgroup of 395 people with mild disease (MMSE 21 to 28), the device was associated with slower decline on several measures, including 56% on daily function and 47% on the CDR-SB rating, according to NeurologyLive. These subgroup p-values are nominal and not adjusted for multiple comparisons. Larger effects reported in people who used the device consistently may reflect adherence bias, which the company acknowledges.

Adverse device effects occurred in 18.3% of active users versus 15.5% on sham; headache and tinnitus were the most common. Seizures were reported in 0.9% versus 0.3%.

Why it matters

  • HOPE was one of the largest tests of non-invasive sensory stimulation for Alzheimer’s, and the overall result was negative.
  • Cognito says it will discuss the results with the FDA and a possible De Novo request for early symptomatic Alzheimer’s. Subgroup findings from a missed trial are generally treated as hypotheses that need confirmation.
  • Spectris holds Breakthrough Device designation but is not authorized for sale.

Learn more: Breakthrough Device designation · Cognito Therapeutics in the Directory · Cognito’s $105M Series C

Share:XLinkedInBlueskyEmail

More news